Schrödinger
Physics-and-AI-based computational drug discovery and materials design — the public Nasdaq-listed Schrödinger (SDGR) platform combines physics-based simulation with machine learning to enable the discovery of novel, highly optimised molecules for drug and materials applications. FY2025 revenue $255.9M (+23%) with software $199.5M and drug discovery $56.4M; ~900 employees across 15 global locations.
The Business
Schrödinger is the public Nasdaq-listed (SDGR) computational drug-discovery and materials-design company built on a 35-year-old proprietary physics-based simulation library combined with modern machine-learning capabilities. The product line spans the software platform (~78% of revenue, sold to pharmaceutical, biotech and materials companies plus academic research institutions) and the drug-discovery program economics (collaboration partnerships with major pharma including a disclosed Novartis collaboration with $5.7M Q1 2025 revenue recognition, plus proprietary pipeline programs SGR-1505, SGR-3515, SGR-5573 and SGR-6016). The company was founded in 1990, has approximately 900 employees across 15 global locations, and went public in February 2020 at a $232.2M IPO. FY2025 total revenue was $255.9M (+23%) with software revenue $199.5M (+10.6%) and drug-discovery revenue $56.4M per Schrödinger’s 10-K and earnings press releases. The Q3 2025 strategic pivot to exit independent clinical development and focus on profitable discovery-stage partnerships is the principal capital-allocation framing.
Customers and Distribution
Schrödinger’s software customer base includes the largest global pharmaceutical companies, the major biotech and biopharma cohort, leading academic research institutions, and materials-discovery customers per the company’s IR disclosures and named-press coverage. The software-revenue trajectory (FY2025 $199.5M, +10.6% growth) is the principal proxy disclosure given Schrödinger does not separately publish a precise customer count. Distribution sits across three principal motions: direct enterprise software-licence sales to pharma and biotech (the dominant revenue channel with ~78% share), direct drug-discovery partnership economics with major pharma collaborators (the Novartis collaboration and other partnerships disclosed across the press cycle with milestone-and-royalty economics), and academic-research-licensing into leading research institutions globally. The P3c GTM-maturity sub-rubric was held at 7 in the v1.6ep pass on the multi-channel distribution and the post-strategic-pivot partnership economics framing.
Model Strategy
Schrödinger is a Verticals-first generative-AI play applied to computational drug discovery and materials design: the strategic bet is that integrated physics-and-AI computational platforms — 35-year-old proprietary physics-based simulation combined with modern ML capabilities — beat AI-only generative platforms on the regulated pharma-and-materials discovery surface where accuracy, explainability and downstream-development risk matter for procurement decisions. The model strategy is supplier-agnostic at the foundation-model layer (Schrödinger develops its own physics-based and ML models rather than depending on external frontier-model providers) with the D4a sub-rubric held at 8 in the v1.6ep pass on the proprietary technical stack and the integration with leading-edge AI capabilities. Above the foundation layer, the principal differentiators are the integrated physics-and-AI platform architecture, the recurring software-revenue base, and the discovery-stage partnership economics that monetise the platform inside pharma collaborator workflows. The D1c portability sub-rubric was held at 7 in the v1.6ep pass on the workflow-embedded enterprise-software depth.
At A Glance
The Numbers
Annualised revenue
Active software customers
Headcount (FTE)
Funding to date
Leadership Team
Schrödinger is a public Nasdaq-listed company (SDGR) with a relatively stable C-suite anchored by Ramy Farid in the CEO role since 2017 and Karen Akinsanya as President of R&D Therapeutics. The strategic pivot through 2025 to exit independent clinical development and focus on profitable discovery-stage partnerships was led from the CEO and CFO offices and disclosed at the Q3 2025 earnings cycle. Senior recruiting has come from pharma R&D and computational-chemistry alumni networks across Merck, Pfizer, Vertex Pharmaceuticals and the broader pharma-discovery cohort. The CFO entry was updated at fact-check — Geoffrey Porges has departed and Richie Jain is the current CFO per a 2025 Schrödinger press release. The prior "M.D." suffix on Porges was incorrect.
IM Framework Scoring
IM’s structured assessment of Schrödinger’s competitive position. The summary below is the headline; expand “Show the full analyst-grade analysis” near the bottom for the per-dimension reasoning and evidence. Methodology →
Funding History
| Date | Round | Raised | Post-money | Lead investor(s) |
|---|---|---|---|---|
| Feb 2020 | IPO | $232.2M | — | Nasdaq listing (SDGR) |
| Apr 2018 | Pre-IPO | $85M | — | Bill & Melinda Gates Foundation Strategic Investment Fund |
| Earlier | Earlier rounds | ~$200M+ | — | Bill & Melinda Gates Foundation & others |
Schrödinger went public on Nasdaq in February 2020 at a $232.2M IPO (ticker SDGR). Prior to the IPO, Schrödinger raised approximately $300M+ in private capital across pre-IPO rounds led by the Bill & Melinda Gates Foundation Strategic Investment Fund, with Google Ventures, ARCH Venture Partners, Bain Capital Life Sciences and others as backers. As a public company, Schrödinger’s commercial framing has shifted from external rounds to operating cash flow, software revenue (~78% of total) and discovery-stage drug-discovery partnership economics. Round-by-round figures from Schrödinger’s SEC filings (S-1 / 10-K / 10-Q), IR investor page and the named-press cycle.
Competitive Landscape
Schrödinger’s competitive set sits in three concentric rings: the AI-native frontier-lab-backed drug-discovery platforms (Isomorphic Labs backed by DeepMind, Chai Discovery, EvolutionaryScale, Generate Biomedicines) that compete on the deep-learning-first generative surface; the established computational-chemistry software incumbents (OpenEye/Cadence Molecular Sciences, Chemical Computing Group, BIOVIA inside Dassault Systèmes) that compete on the broader software-licensing surface; and adjacent AI-pharma plays at the boundary (Recursion Pharmaceuticals, BenevolentAI, Insitro). Schrödinger is unusual in the set because the 35-year-old proprietary physics-based simulation library combined with modern ML capabilities is a structurally different technical heritage from the AI-only generative platforms — the strategic bet is that physics-and-AI integration beats AI-only on the regulated pharma-discovery surface where accuracy and explainability matter for downstream development decisions.
| Competitor | Positioning | Distribution edge | Threat profile |
|---|---|---|---|
| Isomorphic Labs (Alphabet/Google DeepMind) |
AI-native drug-discovery platform spun out of DeepMind; AlphaFold-anchored protein-structure prediction plus de-novo molecular design. The principal AI-native frontier-lab-backed competitor on the computational drug-discovery surface. | Direct pharma partnership deals; Eli Lilly and Novartis partnerships disclosed in 2024-2025; DeepMind technical-research credibility as top-of-funnel. | High — AI-native frontier-lab-backed competitor with structurally different technical heritage (deep-learning-first rather than physics-first). |
| Chai Discovery | AI-native frontier model for drug discovery; Series B with backing from major investors; targeting de-novo molecular design and protein-structure prediction at competitive accuracy benchmarks. | Direct pharma partnership deals; research-credibility-anchored top-of-funnel; emerging customer mix. | Medium-High — structurally symmetric AI-native pure-play; the head-to-head pressure is on the de-novo molecular design surface where Schrödinger’s physics-and-AI integration competes. |
| EvolutionaryScale | Frontier-lab AI for biology; the ESM3 protein language model is a category-defining technical milestone in biological sequence modelling. Backed by major investors with $142M Series A. | Direct biotech and pharma partnership deals; research and academic-community top-of-funnel. | Medium-High — emerging AI-native frontier-lab competitor on the biology-modelling surface; flanking risk on the protein-and-biology side of Schrödinger’s discovery pipeline. |
| Generate Biomedicines | Flagship Pioneering-backed AI-native protein-design and drug-discovery platform; generative biology as the core thesis. $273M Series C at $1.0B+ valuation. | Direct pharma partnership deals; deep Flagship Pioneering biotech-network top-of-funnel. | Medium-High — AI-native protein-design competitor; flanking risk on the generative-biology surface of Schrödinger’s pipeline. |
| OpenEye Scientific / CCG / BIOVIA (OpenEye now Cadence Molecular Sciences; CCG independent; BIOVIA (Dassault Systèmes)) |
Established computational-chemistry software incumbents — OpenEye now inside Cadence Molecular Sciences, Chemical Computing Group (CCG) independent, BIOVIA inside Dassault Systèmes. The principal alternative computational-chemistry-software incumbents to Schrödinger. | Direct pharma and academic-licensing channels; deep pharma R&D installed bases. | Medium — structural-overlap competitors on the computational-chemistry software surface; less direct on the AI integration where Schrödinger has led with physics-and-AI through 2024-2025. |
Pricing benchmark: Schrödinger sells software on per-seat enterprise licences plus partnership-based drug-discovery economics with collaboration milestones and equity stakes in some cases (Novartis collaboration disclosed $5.7M Q1 recognition). Isomorphic Labs, Chai Discovery and Generate Biomedicines monetise primarily through pharma-partnership economics with downstream royalties. OpenEye / CCG / BIOVIA sell on traditional enterprise-software licensing models. The competitive frame is therefore the integrated physics-and-AI computational-platform-of-record motion plus partnership-economics rather than headline per-seat or per-license price.
Potential Risks
The case for Schrödinger at IM Framework 6.56 rests on the 35-year-old proprietary physics-based simulation library combined with modern ML capabilities, the 23% FY2025 revenue growth disclosed in the 10-K, the ~900-employee global organisation, the recurring software-revenue base (~78% of total), and the strategic pivot through 2025 to exit independent clinical development and focus on profitable discovery-stage partnerships. The case against splits into five risks of differing magnitude — with regulatory exposure on pharma applications the most structural, the strategic-pivot execution the most active, AI-native competitor substitution the most adjacent, public-market re-rating the most policy-driven, and capital-position framing the most operational.
Regulatory exposure on pharma applications
Schrödinger operates in a heavily regulated pharma R&D space with FDA, EMA and global pharma-regulator oversight on any drug candidate that progresses through clinical development. The D4c regulatory-exposure sub-rubric was held at 4 in the v1.6ep pass on the multi-jurisdictional regulated-drug-development load. The Q3 2025 strategic-pivot to exit independent clinical development and focus on profitable discovery-stage partnerships was framed in part as a response to the capital intensity and regulatory load of independent clinical development. The principal active variable is whether the discovery-stage partnership model converts into stable software-and-partnership economics over the next 4-6 quarters.
Strategic pivot execution — exit from independent clinical development
The Q3 2025 strategic-pivot to exit independent clinical development was structurally formative. The pipeline programs (SGR-1505, SGR-3515, SGR-5573, SGR-6016) that were being developed internally are being repositioned for partnership economics with pharma collaborators. The bull case is that this trades clinical-development capital intensity for a more capital-efficient discovery-stage partnership model that better matches Schrödinger’s physics-and-AI computational-platform thesis; the bear case is that pharma partnership economics depend on partner cadence and can compress in slower R&D-spending cycles.
AI-native competitor substitution
The principal substitution risk comes from AI-native drug-discovery platforms — Isomorphic Labs backed by DeepMind, Chai Discovery, EvolutionaryScale on biology modelling, and Generate Biomedicines on generative biology. The bull case is that Schrödinger’s physics-and-AI integration delivers accuracy and explainability that pure AI-only generative platforms cannot match at scale on regulated pharma-discovery use cases; the bear case is that as foundation models for biology improve (AlphaFold 3, ESM3, RFdiffusion), the physics-first heritage compresses into a feature rather than a structural moat. The D4f competitive-substitution sub-rubric was held at 6 in the v1.6ep pass on the active-competitor cadence.
Public-market re-rating exposure
Schrödinger is publicly listed on Nasdaq (SDGR) with FY2025 revenue $255.9M (+23%) and FY2026 software-revenue guidance set at 10-15% growth on delayed pharma scale-ups. The public-market valuation has tracked the broader AI-pharma cohort and the discovery-stage partnership cycle through 2024-2025. The bull case is that the strategic pivot plus continued software-revenue growth and partnership cadence supports a re-rating against the AI-pharma cohort; the bear case is that delayed pharma scale-ups and the competitive AI-native cadence compress the valuation re-rating.
Capital-position framing as a public company
As a public company since February 2020, Schrödinger’s capital position sits on the balance sheet rather than in external rounds. The D4d capital-position sub-rubric was held at 7 in the v1.6ep pass on the public-company balance sheet, the recurring software-revenue base and the strategic-pivot toward profitable discovery-stage partnerships. The competitive cohort (Isomorphic Labs backed by Alphabet, Chai Discovery and Generate Biomedicines well-funded as private companies) brings different capital structures, which is a structural risk in head-to-head partnership-procurement.
Recent IM Coverage
- AI Tracker — Healthcare AI cohort May 2026.
- IM Framework Methodology — v1.6ep scoring approach. May 2026.
Show recent press coverage of Schrödinger
- Mar 2026 — Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results.
- Nov 2025 — Schrödinger Reports Third Quarter 2025 Financial Results.
- May 2025 — Schrödinger Reports Strong First Quarter 2025 Financial Results.
- Mar 2026 — Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities.
- Nov 2024 — Schrödinger CEO on making physics the basis of AI drug discovery.
- Mar 2025 — Schrödinger Finally Embraces AI — Is It a Buy?
- Aug 2025 — Schrödinger Q2 2025 Earnings Transcript.
Curated feed of named-source coverage — Schrödinger’s IR investor page for the quarterly earnings cycle and 10-K disclosures, and named-author business and science press (STAT News, Nanalyze, The Motley Fool). We exclude PR-wire reposts of the same release, aggregator round-up pieces and Tracxn/PitchBook subscription summaries. SEC filings (10-K, 10-Q, S-1 historical) are the primary disclosure anchor for the FY2025 revenue figures and the strategic-pivot disclosures cited on this page.
Show the source register for the figures on this page
IM operates a primary-source-where-possible discipline. The figures above come from:
- Revenue: Schrödinger’s FY2025 earnings release discloses total revenue of $255.9M (+23%) with software revenue $199.5M (+10.6%) and drug-discovery revenue $56.4M. Q3 2025 total revenue was $54.3M (+54% YoY) with software $40.9M (+28%) and drug discovery $13.5M (+295%). The FY2026 software revenue guidance was set at 10-15% growth in the Q3 2025 earnings cycle on delayed pharma scale-ups; drug-discovery revenue guidance was increased to $49-52M. We hold FY2025 total revenue at $255.9M per the 10-K filings.
- Software licence customers: Schrödinger does not separately disclose precise software-licence customer counts in its 10-K filings. Named-press coverage (STAT News) references a customer base that includes the largest global pharmaceutical companies, the major biotech and biopharma cohort, leading academic research institutions, and materials-discovery companies. The company homepage is the canonical entry point. We decline-to-publish a precise customer count and reference the software-revenue trajectory as the proxy disclosure.
- Headcount: Schrödinger discloses approximately 900 employees operating from 15 locations globally per the STAT News November 2024 profile and the company’s 10-K filings. The team spans computational chemistry, software development, AI/ML, pharma R&D and partnership-economics roles.
- Capital position (public-company framing): Schrödinger went public on Nasdaq (SDGR) in February 2020 at a $232.2M IPO. Prior to IPO, the company raised approximately $300M+ across pre-IPO rounds led by the Bill & Melinda Gates Foundation Strategic Investment Fund. As a public company, the capital position sits on the balance sheet and is reported via the Schrödinger IR investor page and the 10-K / 10-Q SEC filings. The post-2025 strategic pivot to exit independent clinical development and focus on profitable discovery-stage partnerships is the principal capital-allocation framing.
Methodology & Disclaimer
For metric definitions, source-tier hierarchy, and decline-to-publish rules, see the tracker methodology. Confidence dots (• green / • amber / • red) follow the same convention as the AI Tracker.
Spotted a figure you believe is wrong? Send corrections to info@informationmatters.net.
Information Matters Framework scores are the considered opinion of the IM team — human and AI — applied to publicly-available evidence under a disclosed methodology. They are not statements of fact about the companies scored and they are not investment advice.
